AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.